Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus RAYOS.
BREO ELLIPTA vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid